Welcome to the CSU Knowledge Centre. Featuring an overview of chronic spontaneous urticaria, offering pages that cover epidemiology, burden of disease, pathophysiology, assessment tools, treatment, paediatrics, guidelines and fast facts. Delve into the Disease Overview to further your understanding of chronic spontaneous urticaria.
New: Video presentations from the sponsored satellite symposium ‘The needs of allergic patients and how to address them’ presented by Professor Masatoshi Abe at EAACI 2018.
Recently updated: The Disease Overview section has recently been updated with the latest EAACI guidance on the management of CSU.
Information focusing on primary care, containing videos of patients’ first-hand experiences, video highlights and presentations from key events and real-life case studies presented by experts in the field is also available. Resources include: frequently asked questions in urticaria answered by key opinion leaders, quick reference guides including diagnostic algorithms, and information about the TARGET My Hives application.
Paediatric urticaria - its impact and how diagnosis and management compares to adult recommendations. Doctor Montse Alvaro discusses the challenge of managing paediatric patients where it's strongly recommended that first-generation H1-antihistamines are not prescribed.
Quick reference guides and case study videos dedicated to helping primary care practitioners diagnose, manage and treat. Professor Ana Gimenez-Arnau and Dr Dermot Ryan helped with the development of a downloadable checklist with algorithms, disease and drug information.
Access accredited CMEs 'Managing CSU and its comorbidities: from primary to secondary care' and 'EAACI 2017: The future of urticaria – advances in CSU research', or take part in our e-Learning activities 'Case consults: Changing paradigms in the age of biologics' and 'Best practice in managing CSU: international guidelines versus local practice'.
Watch highlights from key speakers including Marcus Maurer and Marter Ferrer at past events within the fields of dermatology and clinical immunology, such as PAAM, GUF, EADV, EAACI, RADLA and WCD.
FAQs such as how should the UAS7 be used, quick reference guides including a decision tree for wheals/angioedema and diagnostic tests recommended in the EAACI/GA2LEN/EDF/WAO guidelines are some of the resources available.
Frequently asked questions are answered by our expert faculty including Christian Vestergaard, Marta Ferrer and Ana Giménez-Arnau and include 'How do you chose which antihistamine to use in a newly diagnosed patient?'.
12 key points on understanding chronic spontaneous urticaria including: there are currently no validated useful biomarkers and there is currently no known cure with first-line treatment of H1-antihistamines, showing less than 50% symptomatic relief.
Discover first-, second- and third-line treatment options for CSU following the EAACI/GA2LEN/EDF/WAO recommended treatment algorithm. Detailing second generation H1-antihistamines and add-ons including omalizumab, ciclosporin A and montelukast.
Alternatively login via
Back to epgonline.org